Abstract:Cancer-related cognitive impairment (CRCI) is a frequent side effect experienced by an increasing number of cancer survivors with a significant impact on their quality of life. Different definitions and means of evaluation have been used in available literature; hence the exact incidence of CRCI remains unknown. CRCI can be described as cognitive symptoms reported by cancer patients in self-reported questionnaires or as cognitive changes evaluated by formal neuropsychological tests. Nevertheless, association between cognitive symptoms and objectively assessed cognitive changes is relatively weak or absent. Studies have focused especially on breast cancer patients, but CRCI has been reported in multiple types of cancer, including colorectal, lung, ovarian, prostate, testicular cancer and hematological malignancies. While CRCI has been associated with various treatment modalities, including radiotherapy, chemotherapy, hormone therapy and novel systemic therapies, it has been also detected prior to cancer treatment. Therefore, the effects of cancer itself with or without the psychological distress may be involved in the pathogenesis of CRCI as a result of altered coping mechanisms after cancer diagnosis. The development of CRCI is probably multifactorial and the exact mechanisms are currently not completely understood. Possible risk factors include administered treatment, genetic predisposition, age and psychological factors such as anxiety, depression or fatigue. Multiple mechanisms are suggested to be responsible for CRCI, including direct neurotoxic injury of systemic treatment and radiation while other indirect contributing mechanisms are hypothesized. Chronic neuroinflammation mediated by active innate immune system, DNA-damage or endothelial dysfunction is hypothesized to be a central mechanism of CRCI pathogenesis. There is increasing evidence of potential plasma (e.g., damage associated molecular patterns, inflammatory components, circulating microRNAs, exosomes, short-chain fatty acids, and others), cerebrospinal fluid and radiological biomarkers of cognitive dysfunction in cancer patients. Discovery of biomarkers of cognitive impairment is crucial for early identification of cancer patients at increased risk for the development of CRCI or development of treatment strategies to lower the burden of CRCI on long-term quality of life. This review summarizes current literature on CRCI with a focus on long-term effects of different cancer treatments, possible risk factors, mechanisms and promising biomarkers.

Self-reported cancer-related cognitive impairment is associated with perturbed neurotransmission pathways

Neurodegenerative disease pathways are perturbed in patients with cancer who self‐report cognitive changes and anxiety: A pathway impact analysis

Cancer-related cognitive impairment as a key contributor to psychopathology in cancer survivors: implications for prevention, treatment and supportive care

Cancer related cognitive impairment: a downside of cancer treatment

An Evaluation of the Multifactorial Model of Cancer-Related Cognitive Impairment

Cognitive impairment after cancer treatment: mechanisms, clinical characterization, and management

Cancer-related cognitive impairment: updates to treatment, the need for more evidence, and impact on quality of life-a narrative review

Long-Term Cognitive Dysfunction in Cancer Survivors

Cancer-Related Cognitive Impairments (CRCIs) in Non-Central Nervous System Adult Patients: Outcome Measures and Methodology of Assessment: A Literature Review

Identifying Cancer-Related Cognitive Impairment Using the FACT-Cog Perceived Cognitive Impairment

Cancer-Related Cognitive Impairment Associated with APOE rs7412 and BDNF rs6265 in Breast Cancer Survivors

Cognitive impairment following breast cancer treatments: an umbrella review

Characterization of cancer survivors clustered by subjective and objective cognitive function scores

Cognitive impairment in adolescent and young adult cancer patients: Pre-treatment findings of a longitudinal study

Neuroimaging Advances in Chemotherapy-Related Cognitive Impairment: from Clinical to Preclinical Research

Seeing through "brain fog": neuroimaging assessment and imaging biomarkers for cancer-related cognitive impairments

Characterizing cancer-related cognitive impairments and impact on quality of life in women with metastatic breast cancer

Adverse Childhood Experiences and Higher Levels of Stress Are Associated With the Co-occurrence of Cancer-Related Cognitive Impairment and Anxiety

The National Cancer Institute Clinical Trials Planning Meeting to Address Gaps in Observational and Intervention Trials for Cancer-Related Cognitive Impairment

Prevalence of cancer-related cognitive impairment among patients with nasopharyngeal carcinoma: a cross-sectional study

Prevalence and associated factors of chemotherapy‐related cognitive impairment in older breast cancer survivors